← Back to all trials
Not Yet Recruiting
NCT07423481
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Conditions: Obesity & Overweight
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 3000
Sponsor: Nantes University Hospital
Location: Nantes university hospital Nantes
Summary
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Eligibility Criteria
Inclusion Criteria:
* Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
* No objection to the use of their data
* Patients able to complete an online questionnaire (via the internet)
Exclusion Criteria:
• Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection
Source: ClinicalTrials.gov (NCT07423481). StuddyBuddy aggregates publicly available trial information.
